Results 121 to 130 of about 2,233 (157)

Tezepelumab in the Treatment of Uncontrolled Severe Asthma

Annals of Pharmacotherapy, 2022
Objective: To review the pharmacology, efficacy, and safety of subcutaneous tezepelumab in the treatment of severe uncontrolled asthma. Data Sources: The PubMed database and ClinicalTrials.gov were searched using the following terms ...
Jacqueline Feist, Melissa Lipari, Pramodini Kale-Pradhan   +2 more
openaire   +2 more sources

Tezepelumab (Tezspire)

Canadian Journal of Health Technologies, 2022
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments ...
openaire   +1 more source

An overview of the preclinical discovery and development of tezepelumab for the treatment of asthma

Expert Opinion on Drug Discovery, 2023
Tezepelumab is a human IgG2 monoclonal antibody (mAb) that binds to human thymic stromal lymphopoietin (TSLP), preventing its interaction with the receptor and inhibiting multiple downstream inflammatory pathways. TSLP is an alarmin relevant to the pathogenesis of asthma.This article focuses on the significance of TSLP in developing asthma and how ...
Paola Rogliani, Josuel Ora, Maria Gabriella Matera   +2 more
exaly   +4 more sources

The effectiveness and value of tezepelumab for severe asthma

Journal of Managed Care & Specialty Pharmacy, 2022
DISCLOSURES: Drs Rind, Campbell, Pearson, Ms Herce-Hagiwara, Ms Fluetsch, and Ms Herron-Smith report grants from Arnold Ventures; Kaiser Foundation Health Plan, Inc; The Patrick and Catherine Donaghue Medical Research Foundation; Blue Cross Blue Shield of Massachusetts; and California Healthcare Foundation during the course of this study.
David M, Rind, R Brett, McQueen, Serina, Herron-Smith, Belén, Herce-Hagiwara, Eric, Gutierrez, Jon D, Campbell, Noemi, Fluetsch, Steven D, Pearson   +7 more
openaire   +2 more sources

A Pharmacovigilance Analysis of Post-Marketing Safety of Tezepelumab

Journal of Allergy and Clinical Immunology: in Practice
Tezepelumab has shown promising efficacy for adult patients with severe asthma since its approval. However, the post-marketing safety evaluation of tezepelumab is currently lacking.To investigate the post-marketing safety of tezepelumab based on the US Food and Drug Administration Adverse Event Reporting System database.Adverse events (AEs) reported ...
Chongshu Wang
exaly   +3 more sources

Tezepelumab as add‐on treatment for severe asthma

Prescriber, 2023
Tezepelumab (Tezspire) is a new monoclonal antibody therapy for add‐on treatment in adolescents and adults with inadequately controlled severe asthma. This article outlines its mode of action, indication and clinical trial outcomes.
openaire   +1 more source

Tezepelumab for Patients with Severe Uncontrolled Asthma: A Systematic Review and Meta-Analysis

Journal of Asthma and Allergy, 2022
Kingsley N. Ukwaja, Ahmed A Aljohaney, Kota Vidyasagar   +2 more
exaly  

Tezepelumab

Reactions Weekly
  +4 more sources

Tezepelumab bei unkontrolliertem Asthma

Pneumologie, 2021
openaire   +2 more sources

Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma and Perennial Allergy

Journal of Allergy and Clinical Immunology: in Practice, 2021
Jonathan Corren, Janet Griffiths, Christopher S Ambrose   +2 more
exaly